5-Chloro-N-[[[4-[6-fluoro-1,4-dihydro-7-(methylamino)-2,4-dioxo-3(2H)-quinazolinyl]phenyl]amino]carbonyl]-2-thiophenesulfonamide

Elinogrel is a reversible antagonist of the platelet purinergic P2Y₁₂ receptor (K_i = 23 nM) that inhibits platelet aggregation in a human platelet-rich plasma (hPRP) assay (IC₅₀ = 2.81 nM). It inhibits thrombosis in a mouse model of vascular injury induced by iron (III) chloride (FeCl₃) when administered at a dose of 60 mg/kg.

Elinogrel is a direct acting reversible P2Y12 inhibitor, which shows an antiplatelet effect and platelet reactivity associated with cytochrome P 450 2C19 and 3A5 gene polymorphisms.

Store at -20°C